Theseus Says Prioritizing THE-349 Fourth-Generation EGFR Inhibitor For EGFR Mutant Non-Small Cell Lung Cancer; IND On Track For Submission In Q4 2023
Portfolio Pulse from Benzinga Newsdesk
Theseus Pharmaceuticals is prioritizing the development of its fourth-generation EGFR inhibitor, THE-349, for EGFR mutant non-small cell lung cancer. The company plans to submit an Investigational New Drug (IND) application for the drug in Q4 2023.
July 13, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theseus Pharmaceuticals' focus on THE-349 could potentially lead to a new treatment option for EGFR mutant non-small cell lung cancer. The IND submission in Q4 2023 indicates progress in the drug's development.
The prioritization of THE-349 by Theseus Pharmaceuticals indicates the company's confidence in the drug's potential. The planned IND submission in Q4 2023 is a significant step in the drug's development process, which could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100